

LETTER to the EDITOR

**Outcome of Inversion 16 in TKD Positive and Negative Acute Myeloid Leukemia Patients**

*Asian Pac J Cancer Prev*, 17 (4), 2343-2344

Dear Editor

A “considerable number” of acute myeloid leukemia (AML) cases have normal karyotype and “express prognostic markers” such as FLT3-ITD, (internal tandem duplication) and TKD (point mutation), NPM1 and CEBPA (Ishfaq et al., 2012; Ahmad et al., 2014; Renneville et al., 2014). Although, great versatility observed amongst subtypes. The frequency of FLT3-TKD mutations is not equal in all AML subtypes. It showed “preferential occurrence” in the intermediate cytogenetic subgroup in PML-RARA and inv(16) AML (Mead et al., 2007; Li et al., 2012). Various authors reported that TKD mutations are more frequent in inversion 16 groups (Kock 2012). In order to investigate any possible association between TKD mutation and inversion 16 we have analysed 35 adult AML patients for TKD point mutation as described elce

where (Thiede et al., 2002). Briefly genomic DNA was extracted and PCR amplification was performed in a 50 µl reaction buffer. PCR products were digested for 1 hour at 37°C and analysed by 2% agarose gel electrophoresis (Thieda et al., 2002).

The frequency of TKD in different studies varies in general. Some studies reported its incidence 5.8% to 7.7% in AML while some reported its incidence from 8 to 12% (Table 1). Our FLT3-TKD D835 mutation is 14.2% which is very close to the study done by Frohling et al. There are very few studies which analyse the association of TKD with inversion 16. The association of FLT3-TKD mutations with the over all survival is controversial and more difficult to study because of low number of cases (Mead et al., 2007). In order to get more conclusive picture we also examined some important studies which at least comprises of 95 samples (Table 1).

We have examined a small cohort of 35 patients. In order to investigate the role of TKD mutation in over all survival and their association with inv 16, we only investigate those cases who are negative for ITD which is reported as a bad prognostic marker by several authors. Although we have examined a small cohort of patients but we have found strong association between TKD mutation and inversion 16. We just found 1 case of inversion 16 out of 5 TKD mutant cases which is a very high frequency and comparatively this patient showed the over all better survival. We also compared various haematological parameters in TKD positive and TKD negative patients




Figure 1. Survival Analysis

Table 1. TKD Mutations with and without Inversion 16

TKD D835 mutation(%)	No of cases with inversion 16	References
4/97(4.1%)	No inversion 16 mentioned	Elyamy et al 2014
3/91(3.9%)	No inversion 16 mentioned	Liang et al 2003
147/3082( 4.7%)	Out of 119 inv 16 cases only 6 have TKD mutation	Bacher et al 2007
7/97(7.2%)	No inversion 16 mentioned	Abu Duhier et al 2001
30/429(7.0%)	No inversion 16 mentioned	Yamamoto et al 2001
75/979( 7.7)	No inversion 16 mentioned	Thiede et al 2002
16/208( 7.6%)	No inversion 16 mentioned	Moreno et al
56/1053(13.3%)	Out of 420 inv 16 cases only 56 have TKD mutation	Kok et al
25/175(14%)	17% of the patients had FLT# mutation with a 3 fold higher frequency of TKD compared with ITD**	Paschka et al 2013
3/110(2.5%)	No inversion 16 mentioned	Murphy et al
4/113(3.5%)	1/4 has inv 16	Colovic et al 2007
68/617(11%)	No inversion 16 mentioned	Schlenk et al 2008
19/120(15.8%)	No inversion 16 mentioned	Shih et al 2004
11/120(8.5%)	No inversion 16 mentioned	Gari et al 2008
37/672(5.5%)	4/11 has inv 16	Janke et al 2014
32/224(14%)	No inversion 16 mentioned	Frohling et al

\*\*+This study mainly done on group of inv(16) patients

**Table 2. Test of Equality of Survival Distributions for the Different Levels of TKD**

	Overall Comparisons		
	Chi-Square	df	Sig.
Log Rank (Mantel-Cox)	0.001	1	0.981

**Table 3. Independent Samples Test For Variable Parameters**

	Independent Samples Test					
	Levene's Test for Equality of Variances		t-test for Equality of Means			
	F	Sig.	t	df	Sig. (2-tailed)	Mean Difference
Age	1.968	.170	.367	32	.716	3.15
Hb Level	.070	.793	-1.809	30	.080	-1.95
TLC	.153	.698	.630	30	.534	20.08
Blast	.097	.759	.546	25	.590	6.61
Platelets	1.339	.256	-.774	30	.445	-28.21

(Table 3) but we have not found any significant difference between these two groups. In conclusion there is a “preferential occurrence” of inversion 16 and better over all survival with TKD mutant sub types but low sample size is a limitation in this study.

## References

- Abu-Duhier FM, Goodeve AC, Wilson GA, et al (2001). identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. *Br J Haematol*, **113**, 983-8.
- Ahmad F, Mohota R, Sanap S, Mandava S, Das BR (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype indian acute myeloid leukemia patients. *Asian Pac J Cancer Prev*, **15**, 1247-53.
- Frohling S, Schlenk RF, Breitruck J, et al (2002). Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. *Blood*, **100**, 4372-80.
- Ishfaq M, Malik A, Faiz M, et al (2012). Molecular characterization of FLT3 mutations in acute leukemia patients. *Asian Pac J Cancer Prev*, **13**, 4581-5.
- Janke H, Pastore F, Schumacher D, et al (2014). Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. *PLoS ONE*, **9**, 89560
- Kottaridis PD, Gale RE, Frew ME, et al (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. *Blood*, **98**, 1752-9.
- Mead A J, Linch DC, Hills RK (2007). FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia, *Blood*, **110**, 1262-70
- Mukda E, Pintaraks K, Sawangpanich R, Wiangnon S, Pakakasama S (2011). FLT3 and NPM1 gene mutations in childhood acute myeloblastic leukemia. *Asian Pac J Cancer*

*Prev*, **12**, 1827-31

Nakao M, Yokota S, Iwai T, et al (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. *Leukemia*, **10**, 1911-8.

Renneville A, Abdelali RB, Chevret S, et al (2014). Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. *Oncotarget*, **5**, 916-32.

Shahab S, Shamsi T, Ahmed N (2012). Molecular involvement and prognostic importance of Fms-like tyrosine kinase 3 in acute myeloid leukemia. *Asian Pac J Cancer Prev*, **13**, 4203-08

Su L, Gao SJ, Tan YH, Han W, Li W (2013). Associations between age, cytogenetics, FLT3-ITD, and marrow leukemia cells identified by flow cytometry. *Asian Pac J Cancer Prev*, **14**, 5341-44

Thiede C, Steudel C, Mohr B et al (2002). Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. *Blood*, **99**, 4326-35.

**Sadaf Shahab<sup>1\*</sup>, Danish Zahid<sup>1</sup>, Shariq Ahmed<sup>1</sup>, Muhammad Nadeem<sup>1</sup>, Tasneem Farzana<sup>2</sup>, Mehresh Taj<sup>2</sup>, Nuzhat Ahmed<sup>1,2</sup>, Tahir S Shamsi<sup>2</sup>**

<sup>1</sup>Department of Molecular Genetics, <sup>2</sup>Department of Hematology, NIBD Postgraduate Institute of Life Sciences, Karachi, Pakistan

\*For correspondence: sadaf\_shahab99@yahoo.com